onlinesupplementto.docVIP

Online supplement to: RETIGABINE AS ADD-ON TREATMENT OF REFRACTORY EPILEPSY– Swedish cost-utility results Bolin Kristian1, Bj?rkstedt Karin2, Frenning Stefan2, Lars Forsgren3 1Department of economics, Lund University, Sweden; 2GlaxoSmithKline, Solna, Sweden; 3Department of Pharmacology and Clinical Neuroscience, Section of Clinical Neuroscience, Ume? University, Ume?, Sweden. Data Treatment effectiveness and study population The quantitative reduction in seizure frequency among responders was calculated from the average baseline seizure frequency reported in the Brodie et al. study [1], 26.7 seizures per 28 days (Table 1, average for the EMA population). The per-6-month baseline average number of seizures was extrapolated to 160 and it was assumed that the seizure frequency, , among responders was uniformly distributed on the interval baseline frequency. Thus, the average number of seizures, per 6 months, among responders was estimated to 40 (. Drug utilisation Drug utilisation was inferred from average dosing used in the efficacy studies included in the recent meta-analysis mentioned above [1-5,20]. Thus, the following utilisation was assumed for the treatment (retigabine) and the comparator (lacosamide) arm, respectively: 892 and 330 mg/day. Standard-therapy drug utilisation was calculated using information from the recent Swedish study [8] in which 5 different standard therapies were used (standard therapies reflected average doses using carbamazepine, lamotrigine, levetiracetam, topiramate or valproate). Drug unit costs Drug unit costs for drugs used in add-on treatment were taken from TLV (Tandv?rds- och L?kemedelsf?rm?nsverket; the Swedish authority that handles the pharmaceutical subsidy system). The per-day drug cost for standard therapy in our model was calculated as the average unit cost of the 5 standard therapies in the Swedish study, inflated from 2007 unit cost to its 2009 equivalent using the Consumer Price Index published by Statisti